Feb ODAC expected with date likely TBA in near term;milestones in coming months have eliminated need for financing near term-focus w/b on launch to 36 key US Cancer Centers 'upon/if' approval; several Cos were involved in DD with Chemgenex for Omapro EU rts-HSP is making Omapro a feature/focus of emerging oncology line;Approval expected by early March;details of commercialization plan coming in Q1.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.